This webinar will discuss the FDA approval of Ixazomib in combination with two other therapies to treat people with multiple myeloma (a form of blood cancer found in the bone marrow) who have received at least one prior therapy. Ixazomib is the first oral proteasome inhibitor and is approved in combination with lenalidomide and dexamethasone (a type of corticosteroid).
David Steensma, MD, Dana-Farber Cancer Institute, Division of Hematological Malignancies, Boston, MA
Alexandria Schwarsin, MD, Medical Officer, U.S. Food and Drug Administration, Silver Spring, MD
S. Vincent Rajkumar, MD, Edward W. and Betty Knight Scripps Professor of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN